| Idiopathic pulmonary fibrosis: What has changed in the diagnosis and treatment from past to present? | Onur YAZİCİ, Oğuzhan OKUTAN, Aysun ŞENGÜL, Bülent ALTİNSOY, Ceyda ANAR | 1–16 |
| Epidemiology of COVID‑19 | Selma METİNTAS | 2–7 |
| Pathogenesis of COVID‑19 | Evrim Eylem AKPINAR | 8–11 |
| Tobacco and COVID‑19 | H. Volkan KARA, Özlem SÖNMEZ, Sule AKÇAY, Zeynep ATAM TAŞDEMİR | 12–15 |
| Clinical and laboratory findings of COVID‑19 | Berna KOMURCUOGLU | 16–18 |
| Impact of cognitive functions on the quality of spirometry performance in patients with COPD | Mecit SÜERDEM, Fikret KANAT, Baykal TÜLEK, Gülfem YİLDİRİM, Nart Bedin ATALAY | 17–22 |
| Radiological findings of COVID-19 pneumonia | Recep Savas, Naim CEYLAN | 19–24 |
| Retrospective analysis of false positive ratio of our patients with lung cancer at positron emission tomography‑CT screen | Nihal Arzu MİRİCİ, Hasan Oguz KAPICIBASI, Pınar Mutlu, Şahınur Aycan ALKAN, Buse YUKSEL, Çoşkun BAKAR | 23–28 |
| Bronchoscopy and respiratory specimen collection for COVID‑19 | Levent DALAR, Ayperi ÖZTÜRK | 25–28 |
| Factors associated with residual pulmonary thromboembolism detected by computed tomography pulmonary angiography | Özer ÖZDEMİR, Sinem ERMİN, Özgür BATUM, Pelin ÖZDEMİR, Bengi Sari ISLAM, Bahri GÜMÜS, Ufuk YİLMAZ | 29–35 |
| Molecular and serological tests for COVID‑19 | Melahat GURBUZ | 29–34 |
| Potential treatment of COVID‑19 | Cengiz ÖZDEMİR, Nazan ŞEN, Ömer AYTEN, Ülkü AKA AKTÜRK | 35–44 |
| Peak oxygen consumption measurement and postoperative outcome in patients with early‑stage lung cancer | Deniz KOKSAL, Riza DOGAN, Ferhad IBRAHİMOV, Sevinc SARİNC ULASLİ, Erkan DİKMEN, Yigit YİLMAZ, Funda AKSU, Emin MADEN, Salih EMRİ | 36–41 |
| Using fractional exhaled nitric oxide level to differentiate asthma–COPD overlap syndrome from chronic obstructive pulmonary disease |